HomepageEarnings Events Newsdesk 11 hours ago PARSONS CORP (PSN) Q4 2025 Earnings Call PARSONS CORP (NYSE: PSN) Q4 2025 Earnings Conference Merck & Co., Inc. (MRK) KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment » « Agilent Technologies Inc (A) Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC) Newsdesk: